Reach Us +44-1647-403003
Possibility of TAS-102 as an Early Line Therapy Against Advanced Colorectal Cancer | OMICS International | Abstract
ISSN: 2471-8556

Oncology & Cancer Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Case Report

Possibility of TAS-102 as an Early Line Therapy Against Advanced Colorectal Cancer

Taichi Yoshida, Koji Fukuda, Daiki Taguchi, Kazuhiro Shimazu, Masahiro Inoue and Hiroyuki Shibata*

Department of Clinical Oncology, Akita University, Graduate School of Medicine, Japan

*Corresponding Author:
Hiroyuki Shibata
Department of Clinical Oncology
Akita University, Graduate School of Medicine
Hondo 1-1-1, Akita, Japan
Tel: +81188846261
E-mail: [email protected]

Received date: December 12, 2016; Accepted date: December 25, 2016; Published date: December 30, 2016

Citation: Yoshida T, Fukuda K, Taguchi D, Shimazu K, Inoue M, et al. (2016) Possibility of TAS-102 as an Early Line Therapy Against Advanced Colorectal Cancer. Oncol Cancer Case Rep 2:119. doi: 10.4172/2471-8556.1000119

Copyright: © 2016 Yoshida T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Introduction: New drugs have improved the outcome of metastatic colorectal cancer treatment. In Japan, more than 10 agents with at least seven different mechanisms such as 5-fluorouracil (5-FU), irinotecan (IRI), oxaliplatin, angiogenesis inhibitors, anti-epidermal growth factor receptor antibodies, regrafenib, and TAS-102, have been approved. With the increase in the number of alternatives, the importance of choosing the agents increases. To suppress the toxicities of agents is also necessary. To increase the quality of life of the patients should be taken into consideration for their longer survival. TAS-102 has proved to be an effective and safe agent for the 3rd or 4th lines of advanced colorectal cancer.

Presentation of case: We report a case of a patient who had suffered severe adverse events from standard firstline chemotherapy with 5-FU derivative and IRI. She did not want to undergo any more intensive chemotherapy. Toxicity and anxiety made her evade the standard combination chemotherapy. For this patient, TAS-102 achieved over 30% tumor shrinkage and more than 1-year progression-free survival with acceptable toxicities.

Conclusion: TAS-102 can result in a better outcome for a responder when given as an earlier line of therapy. In future, predictive biomarkers of TAS-102 should be identified for better use of this agent.